Lastly, inhibiting the derepressed targets of miR-146a, as shown for IRAK1 in MDS (Rhyasen et al., 2013), constitutes another attractive and feasible therapeutic approach. The gene discussed is IRAK1; the disease is myelodysplastic syndrome.